Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Prudential Financial Inc (PRU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Prudential Financial Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Prudential Financial Inc trades at $112.68 (market cap $40.11B). The key difference: Prudential Financial Inc is far larger — about 8.9× ACADIA Pharmaceuticals Inc.'s market cap, and Prudential Financial Inc pays a 4.85% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PRU | |
|---|---|---|
Market Cap | $4.49B | $40.11B |
Sector | Health | Financials |
52-Week High | $28.06 | $118.72 |
52-Week Low | $20.06 | $92.00 |
Enterprise Value | $3.69B | $67.16B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PRU trades at $115.47, up 2.23% today, with a bullish technical signal and strong moving average support. The company reported a net income margin of 5.5% in 2025, with recent earnings beats in Q1 2026. Recent developments include expansion in India's life insurance market and new ETF launches by PGIM, highlighting growth initiatives.
Outlook remains positive due to solid profitability and strategic expansions, but risks include volatile cash flows and high debt levels. Analyst consensus is cautious with a hold-heavy rating, though the current price exceeds the $98.64 target, suggesting limited near-term upside amid steady operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
